Alzheimer's Disease - Memantine Study
An Open-Label exploratory study with memantine: Correlation between proton magnetic resonance spectroscopy, cerebrospinal fluid biomarkers, and cognition in patients with mild to moderate Alzheimer's Disease
Protocol ID
Protocol Description
The purpose of this study is to gain a better understanding of what happens to brain chemistry and mental ability in patients with moderate Alzheimer's disease who are taking a stable dose of an FDA approved acetylcholinesterase (ACE) inhibitor drug [that is, either donepezil (Aricept®), rivastigimaine (Exelon®) or galantamine (Razadyne®)] and are then given memantine HCl (Namenda™) in addition to their other medication.
Brain chemistry will be evaluated with a type of brain scanning known as magnetic resonance spectroscopy or “MRS” and by testing cerebrospinal fluid (CSF), and mental ability will be evaluated using paper and pencil tests.
Eligibility Criteria
Patients with moderate Alzheimer's disease
Primary Investigator(s)
- Marc L. Gordon, MD